Five inpatients received anti-TNFα therapy following a negative T-SPOT.TB result and two patients had samples collected for a T-SPOT.TB assay; however, due to sample problems, some received anti-TNFα therapy without further delay following a clinical risk vs. benefit decision. This evidence concerns the gene TNF and tuberculosis.